In receptor pharmacology, agonists are classified by two distinct properties: affinity (the ability to bind a receptor) and efficacy (the ability to produce a biological effect upon binding). A partial agonist possesses both affinity and intrinsic efficacy, but its maximal efficacy is lower than that of a full agonist at the same receptor. Saturating all available receptors with a partial agonist will not produce the same ceiling response that a full agonist achieves.
This ceiling effect has meaningful implications for how partial agonists behave in biological systems. In the presence of a full agonist, a partial agonist can act as a functional antagonist by competing for receptor binding whilst delivering a lower net stimulus , effectively reducing the full agonist's response. Conversely, in the absence of a full agonist, it will produce some degree of receptor activation. This dual character is described in the literature as competitive partial agonism.
The concept is central to understanding the pharmacology of several receptor classes studied in cannabinoid and opioid research. Some cannabinoids demonstrate partial agonist activity at CB1 or CB2 receptors, producing submaximal signalling responses compared to high-efficacy reference compounds used in laboratory settings. Classification as a partial versus full agonist is receptor-subtype-specific and depends on the assay system, tissue type, and the reference full agonist used for comparison.
Partial agonism is a mechanistic and pharmacological classification only. It describes a ligand's behaviour at a receptor in a defined experimental context and does not, of itself, indicate any clinical outcome, therapeutic benefit, or safety profile in humans.
Sources: